Tumor Growth Evaluation
Tumor Growth Evaluation - Related Videos
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
0 Views •
Cited by 15 •
2015
This protocol describes a method for the detailed evaluation of leukocyte subsets within the tumor microenvironment in a mouse tumor model. Chemerin-expressing B16 melanoma cells were implanted subcutaneously into syngeneic mice. Cells from the tumor microenvironment were then stained and analyzed by flow cytometry, allowing for detailed leukocyte subset analyses.
07:55
The Influence of Liver Resection on Intrahepatic Tumor Growth
0 Views •
Cited by 6 •
2016
A high incidence of tumor recurrence after resection of liver metastases remains an unsolved problem. The illustrated mouse model may be useful to investigate the reasons for such recurrences. It combines a liver resection model with intrahepatic tumor cell injection for the first time.
09:14
An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
0 Views •
Cited by 39 •
2011
A modified 3-D in vitro system is presented in which growth characteristics of several tumor cell lines in reconstituted basement membrane correlate with the dormant or proliferative behavior of the tumor cells at a metastatic secondary site in vivo.
03:24
ATP-Based Luciferase Viability Assay: A Homogenous Method to Evaluate the Growth-Inhibitory Potential of Test Agents on Tumor Organoids
0 Views •
2025
In this video, we demonstrate a rapid, single-addition assay to assess cell viability in patient-derived organoids upon treatment with a test agent using intracellular ATP levels as a marker for cellular metabolic activity. The intracellular ATP levels are measured using the luciferase/luciferin reaction, where the emitted light intensity indicates the cellular viability and, in turn, the test agent's growth-inhibitory potency.
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
0 Views •
Cited by 17 •
2019
This protocol describes a detailed workflow for the generation and ex vivo characterization of oncolytic viruses for expression of immunomodulators, using measles viruses encoding bispecific T cell engagers as an example. Application and adaptation to other vector platforms and transgenes will accelerate the development of novel immunovirotherapeutics for clinical translation.
FAQs
Each measurement method captures a different aspect of tumor change. Caliper measurements provide size data, medical imaging follows tumors over time, histological analysis examines cellular composition, and proliferation biomarkers indicate cellular activity. Combining these readouts can distinguish changes in overall dimensions from changes in internal tumor biology during progression or treatment.
Standardized time points make growth data comparable within and between experimental groups. Measuring tumors on a consistent schedule allows researchers to follow trends rather than rely on isolated observations. Applying the same approach to treated and comparison groups strengthens assessment of treatment response and helps identify changes that may indicate resistance.
Size alone does not capture every relevant tumor outcome. Changes in cellular composition, proliferation biomarkers, and observed behavior add biological context to dimensional measurements. In cancer research, this combination helps connect tumor progression with treatment effects and supports interpretation of whether a tumor is responding, continuing to develop, or showing resistance.
A basic evaluation workflow begins by selecting the tumor model and measurement approach, then recording observations at defined time points. Researchers may use calipers, imaging, histological analysis, or proliferation biomarkers, depending on the question. Measurements are then compared across time and, when relevant, across treatment groups to characterize outcomes.
Histological analysis is especially useful when researchers need information beyond external or image-based size. Examining tissue can reveal changes in cellular composition, while proliferation biomarkers provide evidence about cell activity. These complementary findings help explain why tumors differ in behavior and can add detail to treatment-assessment results.
Tumor growth evaluation supports studies in cell cultures, animal models, and clinical investigations, although the measurement context differs. Across these settings, standardized growth data help compare experimental outcomes, assess therapeutic strategies, and investigate factors influencing cancer development. The resulting evidence can also contribute to studying progression and treatment resistance.